Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma
| Autor: | Philippine, Lucas, Serge, Boulinguez, Vincent, Sibaud, Loïc, Mourey, Laurence, Lamant, Carle, Paul, Nicolas, Meyer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Proto-Oncogene Proteins B-raf Aniline Compounds Skin Neoplasms Acrylonitrile MAP Kinase Kinase 1 Middle Aged Treatment Outcome Piperidines Vemurafenib Antineoplastic Combined Chemotherapy Protocols Disease Progression Azetidines Humans Female Melanoma Protein Kinase Inhibitors Aged Retrospective Studies |
| Zdroj: | Dermatology (Basel, Switzerland). 234(3-4) |
| ISSN: | 1421-9832 |
| Popis: | Combined treatment with BRAF-V600 and MEK inhibitors has significantly improved progression-free and overall survival of patients with BRAF-mutated melanoma. Pattern of disease progression and outcomes in patients have not been fully characterized.We conducted a single-center, retrospective, descriptive analysis of a cohort of 52 patients treated with BRAF-V600 + MEK inhibitors for advanced melanoma over a 12-month period. The aim of this study was to characterize disease progression, defined as metastatic pattern, disease kinetics, and response to subsequent therapies, in melanoma patients treated with BRAF-V600 + MEK inhibitors.Disease progression was observed in 31/52 (59.6%) patients treated with BRAF-V600 + MEK inhibitors. Relapse of melanoma involved the CNS for 22/31 (70.9%) patients with disease progression, including 18/31 (58%) patients who had exclusive intracranial metastases. Sixteen patients died from disease progression. Among the 31 patients who had disease progression, the median time until a relapse was 8 months, and the median survival time after disease progression was 2 months.Our study shows that, for patients treated with BRAF-V600 + MEK inhibitors who lose response, disease progression was aggressive and had poor outcomes. Most patients had CNS metastases and low rates of therapeutic response to any subsequent therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|